Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 49Rectal Neoplasms 32Pancreatic Neoplasms 28Colonic Neoplasms 24Stomach Neoplasms 19Neoplasm Metastasis 15Neoplasms 13Esophageal Neoplasms 10Breast Neoplasms 7Head and Neck Neoplasms 6Recurrence 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Lymphoma, Extranodal NK-T-Cell 3Liver Neoplasms 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peritoneal Neoplasms 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × HER2 Positive Esophagogastric Cancer × Oxaliplatin × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡